— Know what they know.
Not Investment Advice
Also trades as: BIO (NYSE) · $vol 107M

BIO-B NYSE

Bio-Rad Laboratories, Inc.
1W: +4.2% 1M: +4.0% 3M: +22.7% YTD: +22.1% 1Y: +18.2% 3Y: -6.2% 5Y: -36.8%
$379.50
+15.35 (+4.22%)
 
Weekly Expected Move ±0.3%
$364 $365 $366 $367 $368
NYSE · Healthcare · Medical - Devices · Tech Score Buy · Power 69 · $9.9B mcap · 522410 float · 0.017% daily turnover
Credit Risk of going bust: lower than 70% of companies Debt: 10.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $4.62 (down 99%), Bio-Rad Laboratories, Inc. would be worth roughly what it owes.
Total debt $1.20B against a stock market value of $10.19B.
Distance to default 7.62 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $802.2M (short-term plus half of long-term), stock volatility 36.7%; Altman Z 3.86. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Smart Money Score
No convergence signal
Key Statistics
Market Cap$9.9B
52W Range244.54-381.52
Volume0
Avg Volume88
Beta1.11
Dividend—
Analyst Ratings
9 Buy 2 Hold 0 Sell
Consensus Buy
Company Info
CEONorman D. Schwartz
Employees7,450
SectorHealthcare
IndustryMedical - Devices
IPO Date1999-09-21
1000 Alfred Nobel Drive
Hercules, CA 94547
US
510 724 7000
About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. creates, manufactures, and markets products essential for life science research and clinical diagnostics. Its operations span globally, covering territories such as the United States, Europe, Asia, Canada, and Latin America. The company's business is organized into two main divisions: Life Science and Clinical Diagnostics. The Life Science division develops and provides a comprehensive array of reagents, laboratory apparatus, and instruments. These are vital for various applications, including scientific research methodologies, biopharmaceutical production processes, and food quality testing. This segment dedicates its efforts to key areas within the life sciences, such as proteomics, genomics, biopharmaceutical development, cellular biology, and ensuring food safety. Its diverse clientele includes academic institutions (universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology researchers, and both food producers and testing laboratories. Conversely, the Clinical Diagnostics division specializes in designing, producing, selling, and supporting diagnostic test systems, informatics solutions, test kits, and specific quality control measures for clinical laboratories. This segment furnishes reagents, instrumentation, and software precisely tailored to address particular requirements within the in vitro diagnostics market. Its products are utilized by reference laboratories, hospital labs, state-operated newborn screening facilities, physicians' private offices, and blood transfusion centers. Furthermore, Bio-Rad offers systems and products designed for separating intricate chemical and biological substances, as well as for identifying, analyzing, and purifying their individual components. The company distributes its offerings through a multi-channel approach, leveraging both its direct sales force and a network of distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was established in 1952 and its corporate headquarters are located in Hercules, California.

Recent Insider Trades

NameTypeSharesPriceDate
ENGELHARDT EVA ANETT S-Sale 550 $246.54 2026-05-11
Lakkaraju Roop Kalya M-Exempt 1,078 — 2026-04-24
Lakkaraju Roop Kalya F-InKind 420 $287.84 2026-04-24
Lakkaraju Roop Kalya M-Exempt 1,078 — 2026-04-24
ENLOE COURTNEY C M-Exempt 186 — 2026-04-24

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms